Tendersinfo keep you informed about the latest events in the national and international Procurement Industry. Procurement News provides in-depth coverage of the procurement industry, including contract awards, contract additions, new contract wins, mergers and acquisitions. Tendersinfo through its tender news section provides an update on all domestic and global tendering opportunities, invitation to bid & trade leads.

Publish Date : 30-Jul-2012

Transgene, announces the effective start of operations in its 50:50 Chinese equity joint venture (“EJV”) with Tasly Pharmaceutical Group Co., Ltd. The EJV will initially develop four of Transgene products in the EVJ territories:
1) TG3003, a monoclonal antibody for development in inflammation and cancer,
2) TG1050, an HBV therapeutic vaccine recently selected for development,
3) TG4040, an HCV therapeutic vaccine currently in phase 2 clinical trials, and
4) TG6002, a second generation oncolytic virus developed in cancer.

The EJV will initially focus on technology transfer from Transgene for the pharmaceutical development of the products locally. The EJV will subcontract most of its research and development activities to Tasly and to third-parties so as to focus on project management as well as on medical and regulatory development. A first clinical trial is expected to start in 2015.

Upon registration, the EJV will distribute and commercialize the products, directly or through distribution agreements with Tasly.
The EJV will be staffed locally, with the CEO appointed by Transgene.

Tasly and Transgene will respectively invest 5.3 and 2.6 million euros in a first capital increase of the EJV. Transgene will also contribute intellectual property rights so as to balance the equity ownership of the EJV at 50:50 with Tasly.

Transgene will retain exclusive rights to its products outside of the EJV territories.

The EJV intends to develop additional products, including non-Transgene products in-licensed for their development and commercialization in the EJV territories.

“We are extremely happy to start our operations in our joint venture with the Tasly Group. Since we have started this venture, we have had very constructive and fruitful discussions with Tasly that have led to a very ambitious business plan, now being put in motion” stated Philippe Archinard, Chairman and CEO of Transgene. He added: “We are convinced that China is soon going to become one of the largest markets for biopharmaceuticals and the products selected for development address large local unmet medical needs such as HCV or HBV. With Tasly, we share a long term industrial vision and we have the right group of talented person to jointly develop these promising drugs that we hope will make a difference for patients’ lives, in China and globally”.

Go to previous page